lncRNA TUG1和PCAT-1表达水平与多发性骨髓瘤预后的关系及其诊断价值分析

目的探讨长链非编码RNA(lncRNA)牛磺酸上调基因1(TUG1)和前列腺癌相关转录产物1(PCAT-1)在多发性骨髓瘤(MM)患者血清中的表达水平及与预后的关系,并探讨其诊断价值。方法选取2013年1月至2016年11月于该院住院治疗的MM患者90例作为MM组,另选取90例健康体检者作为对照组。采用实时荧光定量PCR检测血清lncRNA TUG1和PCAT-1的表达水平;分析lncRNA TUG1和PCAT-1的表达水平与临床病理特征的关系;分析lncRNA TUG1和PCAT-1的表达水平与MM患者预后的关系;采用COX风险回归模型分析影响患者预后的危险因素;使用受试者工作特征(ROC)曲线分析TUG1和PCAT-1对MM的诊断价值。结果MM组患者的血清lncRNA TUG1和PCAT-1表达水平高于对照组(P<0.05);lncRNA TUG1高表达组与低表达组、lncRNA PCAT-1高表达组与低表达组在年龄、β2微球蛋白和Ca2+水平方面比较,差异均有统计学意义(P<0.05);lncRNA TUG1高表达组3年生存率低于lncRNA TUG1低表达组(P<0.05),lncRNA PCAT-1高表达组3年生存率低于lncRNA PCAT-1低表达组(P<0.05)。多因素COX风险回归模型分析显示,年龄较大、β2微球蛋白水平较高、lncRNA TUG1高表达和PCAT-1高表达是影响MM患者预后的危险因素(P<0.05)。血清lncRNA TUG1的曲线下面积为0.777(95%CI:0.704~0.850);血清lncRNA PCAT-1的曲线下面积为0.648(95%CI:0.566~0.729)。结论血清lncRNA TUG1和PCAT-1在MM患者中高表达,lncRNA TUG1辅助诊断MM的价值优于lncRNA PCAT-1,血清lncRNA TUG1和PCAT-1表达水平与MM患者的预后相关。     

长链非编码RNA DLX6-AS1在肿瘤中的研究进展

近年来,长链非编码RNA(lncRNA)可作为抑癌或促癌因子参与肿瘤的多种生物过程,包括增殖、抗凋亡、侵袭和迁移,其异常表达与患者预后、临床病理学特征及耐药紧密相关。DLX6-AS1是最近发现的一种新型lncRNA,其在多种恶性肿瘤中表达上调,并与肿瘤预后、TNM分期、淋巴结转移和远处转移相关,且可与多种微小RNA相互作用调节下游靶基因及相关信号通路发挥促癌作用。该文就lncRNA DLX6-AS1参与人类肿瘤的生物学过程和调控机制作一综述。     

多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究

目的 探究多发性骨髓瘤(MM)中血清长链非编码RNA(lncRNA)转录产物1(PCAT-1)的表达水平及临床应用价值。方法 选取肇庆市第二人民医院72例MM患者作为研究对象,另选取同期在该院进行体检的60例正常者作为对照组,RT-PCR法测定血清中lncRNA PCAT-1表达; 分析lncRNAPCAT-1的表达与临床病理参数、治疗效果的关系,采用Kaplan-Meier对5年生存情况进行分析,Log-Rank法检测生存差异。结果 MM组血清中 PCAT-1mRNA表达量2.65±0.64高于对照组1.06±0.23,差异有统计学意义(t=18.276,P=0.000)。PCAT-1 mRNA高表达组、低表达组在性别、临床分期、病理分型及血红蛋白、浆细胞、血小板、清蛋白、β2-MG和CRP方面对比,差异均无统计学意义(χ²=0.001～3.345,均P>0.05)。Ca²⁺≥10 mg/dl高表达组患者比例(57.14%)明显高于低表达组(27.27%),差异有统计学意义(χ²=4.157,P=0.041; χ²=5.229,P=0.022)。PCAT-1低表达组、高表达组治疗有效率对比(88.64% vs 75.00%),差异无统计学意义(χ²=2.291,P=0.130)。PCAT-1高表达、低表达组无生存进展(PFS)、总体生存(OS)曲线对比,差异有统计学意义(χ²=7.269,P=0.007; χ²=9.190,P=0.002)。COX风险回归多因素分析显示年龄、PCAT-1mRNA表达量为影响患者预后的独立因素(OR=3.275,P=0.025,95%CI:2.691～3.761; OR=2.136,P=0.046,95%CI:2.034～2.685)。结论 lncRNA PCAT-1在MM患者血清中呈高表达,并与患者的预后相关。     

长链非编码RNA H19在肿瘤中的研究进展

长链非编码RNA(long noncoding RNA,lncRNA)与肿瘤的发生、发展密切相关。H19是位于人类染色体11p15.5上,长度为2 300 bp,并可与胰岛素样生在因子2(IGF-2)相互作用,表现出父系印记的lncRNA分子。近年来的研究发现,H19在多种肿瘤中的表达异常,且与患者的不良预后紧密相关,H19可与多种癌基因或抑癌基因(如c-Myc、p53)以及microRNA(miRNA)相互作用,从而在肿瘤的生长、增殖、分化凋亡及侵袭转移等过程中发挥重要功能。进一步研究H19的生物学功能及具体作用机制,有助于深入了解肿瘤的特性,为肿瘤的早期诊断、预后判断及基因治疗提供依据。     

结直肠癌组织中lncRNA FOXC2-AS1与EZH2的表达及临床意义

目的探讨结直肠癌(CRC)组织中长链非编码RNA(lncRNA)RNA FOXC2-AS1、Zeste基因增强子同源物2(EZH2)表达及临床意义。方法采用实时荧光定量PCR检测86例CRC癌组织和癌旁组织中lncRNA FOXC2-AS1、EZH2的表达。采用免疫组化法检测癌组织和癌旁组织中EZH2的蛋白表达。采用Pearson相关分析lncRNA FOXC2-AS1与EZH2表达的相关性。统计学分析癌组织中lncRNA FOXC2-AS1、EZH2的表达与临床病理特征之间的关系。Kaplan-Meier生存曲线分析不同lncRNA FOXC2-AS1、EZH2表达水平患者的5年总体生存率的差异。结果与癌旁组织比较,癌组织中lncRNA FOXC2-AS1及EZH2 mRNA表达水平升高(P<0.05),EZH2蛋白表达阳性率较高(P<0.05)。癌组织中lncRNA FOXC2-AS1与EZH2 mRNA表达水平呈正相关(r=0.623,P<0.05)。癌组织中lncRNA FOXC2-AS1及EZH2表达与肿瘤分期有关(P<0.05),与患者的性别、年龄、肿瘤大小、肿瘤位置、肿瘤分化程度及是否伴淋巴结转移无关(P>0.05)。Kaplan-Meier生存曲线分析结果显示lncRNA FOXC2-AS1及EZH2高表达的患者5年总体生存率低于lncRNA FOXC2-AS1及EZH2低表达患者(P<0.05)。结论CRC癌组织中lncRNA FOXC2-AS1及EZH2表达水平升高,lncRNA FOXC2-AS1及EZH2的高表达与肿瘤分期有关,二者有望成为新的评价肿瘤预后的分子标志物。     

Lnc RNA PVT1通过LATS2对宫颈癌生物学行为及预后的影响

目的 探讨长链非编码RNA PVT1(lncRNA PVT1)通过大型肿瘤抑制因子2(LATS2)对宫颈癌生物学行为及预后的影响。方法 利用荧光定量实时PCR(qRT-PCR)测定成对的癌及癌旁组织lncRNA PVT1、LATS2的表达。在Hela细胞中转染PVT1 siRNA,观察PVT1下调对LATS2表达量的影响。结果 lncRNA PVT1在宫颈癌组织中表达水平明显高于癌旁正常组织（P<0.05）,LATS2的表达水平明显低于癌旁正常组织（P<0.05）,两者表达为负相关。lncRNA PVT1沉默能够显著降低Hela细胞的增殖、迁移、侵袭能力（均P<0.05）,并增加Hela细胞的凋亡率（P<0.05）。lncRNAPVT1高表达患者的生存时间明显短于低表达者（P<0.05）。FIGO临床分期、淋巴结转移、肿瘤浸润深度及ncRNA PVT1表达水平都可作为宫颈癌患者独立的预后因子（P<0.05）。结论 lncRNA PVTl能够抑制LATS2表达而增强癌细胞的增殖、迁移、侵袭能力,降低癌细胞的凋亡率,且lncRNA PVTl表达可作为宫颈...     

长链非编码RNA OIP5-AS1在肿瘤中的研究进展

长链非编码RNA(long non-coding RNA,lncRNA)与肿瘤的发生发展密切相关。LncRNA反义Opa反应蛋白5RNA(Opa interacting protein 5-antisense RNA 1,OIP5-AS1)在多种肿瘤中不仅异常表达,还发挥癌基因的作用,是潜在的肿瘤治疗靶点,并有望成为肿瘤诊断和预后新的标志物。本文就近年来OIP5-AS1在肿瘤中作用的相关研究作一综述,以期为OIP5-AS1的临床应用提供依据。     

长链非编码RNA在消化系统肿瘤中的研究进展

长链非编码RNA（lncRNA）是一系列广泛转录自人及其他哺乳动物基因组的长度超过200 nt的核苷酸片段,通常没有蛋白编码功能,一度被认为是基因组的转录“噪音”。近年来一些 lncRNA 被发现具有多种生物学功能,成为分子生物学领域研究的热点。已经在多种肿瘤中发现有lncRNA的异常表达,并且异常表达的 lncRNA 和肿瘤的复发、转移及预后有关。本文中将探讨近期发现的与消化系统肿瘤相关的lncRNA,部分着重于具有促癌作用的lncRNA,以期为消化系统肿瘤的诊断、预后及分子治疗提供线索。     

长链非编码RNA在乳腺癌中的研究进展

长链非编码RNA(long non-coding RNA,lncRNA)是非编码RNA(non-coding RNA,ncRNA)的重要组成部分。研究发现,lncRNA在乳腺正常发育及肿瘤发生过程中具有重要作用,其表达水平的改变与乳腺癌发生、发展、转移和耐药密切相关,可作为乳腺癌诊断、疗效预测和预后评估的重要生物学标志物。近年来,随着高通量测序技术的发展以及生物信息学分析方法的丰富,与乳腺癌相关的lncRNA被大量发现和验证。为此,该文就lncRNA在乳腺癌中的最新研究进展作一综述。     

LncRNA在胃癌早期诊断中的研究进展

胃癌是起源于胃黏膜上皮细胞的恶性肿瘤,在我国各种恶性肿瘤发病率中居首位。长非编码RNA(lncRNA)是癌症研究中的最热门非编码RNA之一。在胃癌中的作用也得到广泛研究,lncRNA是肿瘤生物学的重要组成部分。此外,有研究表明,与健康个体比较,胃癌患者lncRNA表达异常。在传统胃癌检测方式(内镜、病理检查和血清生物标志物测定)的基础上有研究表明lncRNA也能用于胃癌的诊断,具有高灵敏度、高特异度、非侵入性和成本低廉等优点;其与常规肿瘤标志物联合诊断的准确度更高,可作为理想的生物标志物,对早期胃癌进行检测。该文简述了lncRNA在胃癌中的研究进展。     

外泌体lncRNA在肿瘤中的研究进展

外泌体是肿瘤液态活检的明星分子,作为"胞间通讯"的信使可以在全身体液循环.随着科学家们对长链非编码RNA(lncRNA)的深入研究,发现lncRNA在表观遗传修饰、转录调控与转录后调控等多个层面发挥作用.在肿瘤发生、发展过程中,外泌体携带的lncRNA能够改变肿瘤微环境,介导肿瘤细胞增殖、转移和耐药,促进血管生成和介导...     

Immune‐related eight‐lncRNA signature for improving prognosis prediction of lung adenocarcinoma

BackgroundLung adenocarcinoma (LUAD) is the leading cause of cancer‐related deaths worldwide. Therefore, the identification of a novel prediction signature for predicting the prognosis risk and survival outcomes is urgently demanded.MethodsWe integrated a machine‐learning frame by combing the Cox regression and Least Absolute Shrinkage and Selection Operator (LASSO) regression model to identify the LUAD‐related long non‐coding RNA (lncRNA) survival biomarkers. Subsequently, the Spearman correlation test was employed to interrogate the relationships between lncRNA signature and tumor immunity and constructed the competing endogenous RNA (ceRNA) network.ResultsHerein, we identified an eight‐lncRNA signature (PR‐lncRNA signature, NPSR1‐AS1, SATB2‐AS1, LINC01090, FGF12‐AS2, {"type":"entrez-nucleotide","attrs":{"text":"AC005256","term_id":"11993971"}}AC005256.1, MAFA‐AS1, BFSP2‐AS1, and CPC5‐AS1), which contributes to predicting LUAD patient''s prognosis risk and survival outcomes. The PR‐lncRNA signature has also been confirmed as the robust signature in independent datasets. Further parsing of the LUAD tumor immune infiltration showed the PR‐lncRNAs were closely associated with the abundance of multiple immune cells infiltration and the expression of MHC molecules. Furthermore, by constructing the PR‐lncRNA–related ceRNA network, we interrogated more potential anti‐cancer therapy targets.ConclusionlncRNAs, as emerging cancer biomarkers, play an important role in a variety of cancer processes. Identification of PR‐lncRNA signatures allows us to better predict patient''s survival outcomes and disease risk. Finally, the PR‐lncRNA signatures could help us to develop novel LUAD anti‐cancer therapeutic strategies.     

Immune‐related lncRNA signature delineates an immune‐excluded subtype of liver cancer with unfavorable clinical outcomes

BackgroundLong non‐coding RNAs (lncRNAs) play crucial roles in immune regulation and, therefore, may be closely related to the tumor microenvironment (TME). However, there are few studies regarding the relationship between the lncRNAs and the TME in liver cancer.MethodsFirstly, we constructed a lncRNA signature based on the top 10 immune‐inversely related lncRNAs obtained from the ImmLnc database and performed disease‐free survival (DFS) and overall survival (OS) analyses for the patients included in the Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA‐LIHC) stratified by the lncRNA signature. Then, we explored the relationship between the lncRNA signature with distinct mutation profiles and the tumor microenvironment (TME).ResultsThe lncRNA signature was successfully constructed and verified by survival analysis. The high lncRNA signature was correlated with a decreased DFS and OS in liver cancer and other two gastrointestinal cancers. The mutation profiles showed that the Lnc_high group had a higher number of mutations on many genes, mostly enriched in p53 and WNT pathways. The TME results showed that the Lnc_high group had the highest proportion (51%) of lymphocyte depletion‐characterized immune subtype, and a higher expression of immune checkpoint molecules such as LAG3, PD‐L1, CTLA4. On the contrary, in the Lnc_low group, infiltrating immune‐cell proportions were significantly higher, and a significant enhancement of four axes of the cancer immunity cycle immunogram was observed in this group.ConclusionsThe lncRNA signature we constructed identified an immune‐excluded subtype of liver cancer with unfavorable clinic outcomes, which could be tested as a biomarker for immunotherapy in the future.     

癌组织lncRNA H19和血清前列腺特异抗原水平与前列腺癌病理特征及预后的相关性

目的分析癌组织长链非编码RNA(lncRNA)H19和血清前列腺特异抗原(PSA)水平与前列腺癌(PCa)病理特征及预后的相关性。方法选取89例PCa患者作为病例组,选取同期100例良性前列腺增生患者作为对照组,对两组患者术中切除前列腺组织lncRNA H19相对表达量和血清PSA水平进行检测。结果病例组患者病灶组织中lncRNA H19相对表达量和血清PSA水平均高于对照组。高lncRNA H19表达组患者的总生存期(OS)和无进展生存期(PFS)均低于低lncRNA H19表达组(P<0.05)。Cox风险回归模型分析结果显示,前列腺患者术后OS与病灶组织lncRNA H19相对表达量、临床分期、淋巴结转移情况、Gleason评分、分化程度具有相关性;术后PFS与病灶组织lncRNA H19相对表达量、淋巴结转移情况、Gleason评分具有相关性(P<0.05)。结论PCa癌组织中存在lncRNA H19相对表达量上调,其表达水平与肿瘤的病理特征和患者的预后具有相关性,可作为预测患者预后的辅助指标和潜在治疗靶点,患者术前血清PSA水平虽与病理特征具有相关性,但与患者的预后缺乏相关性。     

Serum exosomal long noncoding RNA CRNDE as a prognostic biomarker for hepatocellular carcinoma

BackgroundAccumulating evidence has shown that long noncoding RNA (lncRNA) CRNDE functions as an oncogene in many cancer types. However, its clinical value has not yet been explored in hepatocellular carcinoma (HCC).MethodsA total of 166 patients with HCC and 100 healthy volunteers were enrolled in this study. The expression levels of serum exosomal lncRNA CRNDE were detected in patients with HCC and controls by quantitative real‐time PCR (qRT‐PCR).ResultsThe serum exosomal lncRNA CRNDE expression levels were significantly increased in patients with HCC compared with normal controls. High serum exosomal lncRNA CRNDE expression was significantly associated with tumor size, tumor differentiation, and TNM stage. Receiver operating characteristic (ROC) analysis revealed that an area under the ROC curve (AUC) of 0.839, with a sensitivity and specificity of 69.3% and 85.0%. In addition, the overall survival (OS) and disease‐free survival (DFS) were significantly longer in patients with lower serum exosomal lncRNA CRNDE expression compared to those with higher CRNDE expression. Moreover, HCC patients with cirrhosis had worse OS and DFS than those without cirrhosis. Univariate and multivariate analyses indicated that high serum exosomal lncRNA CRNDE expression was an independent indicator of poor prognosis.ConclusionTaken together, serum exosomal lncRNA CRNDE might serve as a potential biomarker for HCC diagnosis and prognosis.